"Tamoxifen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.
| Descriptor ID |
D013629
|
| MeSH Number(s) |
D02.455.426.559.389.150.700.900
|
| Concept/Terms |
ICI-46474- ICI-46474
- ICI 46474
- ICI46474
- ICI-46,474
- ICI 46,474
- ICI46,474
|
Below are MeSH descriptors whose meaning is more general than "Tamoxifen".
Below are MeSH descriptors whose meaning is more specific than "Tamoxifen".
This graph shows the total number of publications written about "Tamoxifen" by people in this website by year, and whether "Tamoxifen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 3 | 1 | 4 |
| 1996 | 2 | 3 | 5 |
| 1997 | 5 | 4 | 9 |
| 1998 | 4 | 2 | 6 |
| 1999 | 2 | 5 | 7 |
| 2000 | 4 | 2 | 6 |
| 2001 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 5 | 4 | 9 |
| 2004 | 8 | 2 | 10 |
| 2005 | 8 | 8 | 16 |
| 2006 | 4 | 2 | 6 |
| 2007 | 0 | 2 | 2 |
| 2008 | 2 | 1 | 3 |
| 2009 | 5 | 3 | 8 |
| 2010 | 3 | 5 | 8 |
| 2011 | 5 | 6 | 11 |
| 2012 | 4 | 6 | 10 |
| 2013 | 1 | 5 | 6 |
| 2014 | 3 | 9 | 12 |
| 2015 | 2 | 1 | 3 |
| 2016 | 3 | 4 | 7 |
| 2017 | 1 | 6 | 7 |
| 2018 | 1 | 4 | 5 |
| 2019 | 0 | 4 | 4 |
| 2020 | 1 | 5 | 6 |
| 2021 | 1 | 3 | 4 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tamoxifen" by people in Profiles.
-
Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast Cancer. JAMA Oncol. 2024 Oct 01; 10(10):1379-1389.
-
In memory of V. Craig Jordan (1947-2024): "Father of tamoxifen" and discoverer of SERMs. J Steroid Biochem Mol Biol. 2024 Nov; 244:106598.
-
Breast Articles From 2023: Informing Practice Across the Continuum of Care. Ann Surg Oncol. 2024 Jul; 31(7):4470-4476.
-
Racial and Ethnic Disparities in Outcomes After Breast-Conserving Therapy and Endocrine Therapy for DCIS: A Post-Hoc Analysis of the NSABP B-35 Randomized Clinical Trial. Ann Surg Oncol. 2023 Dec; 30(13):8404-8411.
-
MicroRNA regulation of the serine synthesis pathway in endocrine-resistant breast cancer cells. Endocr Relat Cancer. 2023 11 01; 30(11).
-
Steroid receptor coactivator 3 is a key modulator of regulatory T cell-mediated tumor evasion. Proc Natl Acad Sci U S A. 2023 06 06; 120(23):e2221707120.
-
Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial. J Clin Oncol. 2023 04 01; 41(10):1841-1848.
-
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT. J Clin Oncol. 2023 03 01; 41(7):1370-1375.
-
A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer. Cancer Res. 2022 10 17; 82(20):3673-3686.
-
14-3-3t drives estrogen receptor loss via ERa36 induction and GATA3 inhibition in breast cancer. Proc Natl Acad Sci U S A. 2022 10 25; 119(43):e2209211119.